Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T22:16:48.730Z.
Calculation as of: 2026-10-06T22:16:48.730Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 787788ea5c712995087b0511470a3bc1500b131fb4a88c1f5ff44ca2612ce4c8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$51.19M
PS Ratio
N/A
TTM Avg
1214.61
3Y Avg
1444.04
5Y Avg
930.10
Market Cap
$52.60M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| eXoZymes, Inc. (EXOZ) | $51.23M | N/A | N/A | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A | 1214.61 | 1444.04 | 930.10 |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $51.88M | N/A | 51.20 | 31.27 | 27.74 |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $50.28M | 0.27 | 0.38 | 0.71 | 0.59 |
| Envoy Medical, Inc. (COCH)vs › | $50.27M | 242.85 | 158.30 | 158.03 | 959.94 |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | N/A | N/A | N/A | N/A |
| INmune Bio, Inc. (INMB)vs › | $49.71M | N/A | 1293.91 | 1758.59 | 3330.34 |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | 3.49 | 2.63 | 1.90 | 4.28 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
